Thirty years ago, PDRN was approved as a wound-healing drug in Italy.

Today, it’s K-beauty’s defining ingredient of 2026, showing up in toners, serums, sunscreens, and more.

Medicube alone has sold 50M+ PDRN units and launched across 1,400 Ulta stores last August.

But the problem with the active is that its molecules are large and negatively charged, both properties that block skin penetration. Which means most topicals on shelves right now are doing less work than their marketing suggests. That has made delivery the real battleground.

Companies are taking wildly different approaches to solve the problem.

For example, Amorepacific’s BluePDRN engineers a microalgae-derived variant 1/20th the size of salmon PDRN, solving the problem at the molecular level. VT Cosmetics and others are approaching it through encapsulation and microneedle delivery instead. No single approach has pulled ahead yet.

PDRN is not an isolated story. It is part of Glass Skin 2.0: K-beauty moving past dewy 10-step routines into clinic-grade, biology-driven products.

Our latest K-beauty trends report maps five of these shifts: regenerative biomolecules, precision fermentation, microbiome-focused skincare, Hanbang modernization, and waterless formats.

For each one, we covered the patent activity, the unsolved technical problems, who is staking positions, and where the white space is.

Grab the full report for free here.